Cerebral vasospasm is a serious complication following aneurysmal subarachnoid hemorrhage (SAH); it causes delayed cerebral ischemia (DCI) 
Ischemic events secondary to vasospasm lead to confusion and decreased level of consciousness with focal neurological deficits which may be preceded by worsening headache and increased blood pressure. 1 In 1951, cerebral artery spasm was first described using cerebral angiography by percutaneous puncture of the carotid artery, 7 followed by a few studies describing the time course of vasospasm. 8 
Key defInItIons
The definition of cerebral vasospasm depends on the era and tool used to define the vasospasm. In 1951, Ecker and Riemenschneider defined arterial vasospasm as recognized arteriographically when a vessel is a larger caliber in a subsequent angiogram than it was in a prior angiogram under identical circumstances. 7 Later, angiographic vasospasm was defined as narrowing of the dye column in the major cerebral arteries, which is usually focal but can be diffuse and is rarely identified before day 4 following aneurysmal SAH. 1 Clinical vasospasm, as a syndrome, occurs due to ischemic events secondary to cerebral artery narrowing, characterized by the insidious onset of confusion, decreased consciousness, and worsening headache which may be associated with increased blood pressure. 1 During the current era, definitions of vasospasm have expanded to include clinical or symptomatic vasospasm, angiographic vasospasm, and transcranial Doppler (TCD) vasospasm. Clinical or symptomatic vasospasm has the same definition as in earlier periods but requires ruling out other possible causes of worsening symptoms, such as hydrocephalus, seizures, infections, fever, metabolic imbalances, and oversedation. 9 Angiographic or radiologic vasospasm is categorized by the degree of narrowing; 1-50% is mild vasospasm, 51-75% is moderate, and >75% is severe vasospasm. 10, 11 It can involve proximal vessels, distal vessels, or both and does not necessarily manifest as clinical vasospasm. Transcranial Doppler vasospasm is defined as a mean flow velocity in the middle cerebral artery (MCA) that exceeds 120 cm/sec, or Lindegaard ratio (middle cerebral artery mean flow velocity/extracranial internal carotid artery mean flow velocity) >6.
9,10
Delayed cerebral ischemia (DCI) is a neurologic deterioration presumed secondary to cerebral ischemia that cannot be explained by other systemic or neurologic condition and lasts for more than 1 hour.
epIdemIology outcomes of AneurysmAl sAH
Subarachnoid hemorrhage is one of the most challenging neurological emergencies. The incidence of aneurysmal SAH is 2 to 16 per 100,000 population. 4, 12 In the United States, the incidence is 9.7 per 100,000 population. 4, 13 The median case fatality rate (CFR) in the US was 32.2% and has declined over the last three decades; the CFR is higher in Europe and lower in Japan.
14 In 50% of cases, large artery narrowing will evolve to be visible angiographically and causes ischemic neurological symptoms.
pAtHopHysIology
Rupture of a cerebral aneurysm results in deposition of blood in the subarachnoid space and release of free hemoglobin. 2, 15 Consequently, microglia, the immunomodulatory cells in the central nervous system (CNS), are activated. 15 Microglia stimulate cell adhesion molecules on the luminal surface of endothelial cells, 15 which allows peripheral immune cells like macrophages and neutrophils to bind to endothelial cells and enter the subarachnoid space to clear the free hemoglobin. 2, 15 The absence of lymphatics in the CNS, impaired cerebrospinal fluid (CSF) circulation due to SAH, 2 and the restoration of endothelial tight junction barriers 15 trap macrophages and neutrophils in the subarachnoid space. 2, 15 These trapped cells undergo degranulation and release of inflammatory factors, like endothelin and free radicals; this inflammatory process induces arterial vasoconstriction. 2, 15 There are two phases of this inflammatory process, an initial or acute phase occurs 1-3 days after the primary injury, 16 mediated by macrophages and neutrophils, and a delayed phase, mediated by inflammatory products from degranulation of the acute phase cells, occurs in days to weeks. 2 Cortical spreading depression (CSD) or cortical depolarization is a phenomenon described in several neurological injuries. It was first hypothesized to be a part of the migraine pathophysiology; 17 recently it was related to DCI following aneurysmal SAH. 18 Cortical spreading depression is a self-propagating wave of neuronal and glial depolarization, redistribution of ions inside and outside brain cells, and eventual loss of membrane potential. [19] [20] [21] As a response to brain injury, glutamate is released leading to stimulation of sodium and calcium channels which results in cation influx and neuronal swelling. This process is described as a glutamate excito-toxicity. To restore the normal membrane gradient, oxygen and energy requirements of cells and ion pumps increase to reverse the disrupted ionic hemostasis. In healthy brain tissue, hyperemia induced by vasodilation via nitric oxide and arachidonic acid metabolites increases blood flow and consequently oxygen delivery and is a normal hemodynamic response. However, in injured cells after aneurysmal SAH, this process of hyperemia fails and is replaced by vasoconstriction (inverse of the normal hemodynamic response) and consequently hypo-perfusion and ischemia. Cortical spreading depression continues to "spread the ischemia" to surrounding brain tissues. [18] [19] [20] [21] • Cerebral vasospasm is the major determinant of disability and mortality after aneurysmal subarachnoid hemorrhage after the aneurysm has been secured.
• Monitoring is clinical, radiographic, and physiologic.
• Cerebral vasospasm is a monophasic illness that typically lasts days.
• The main endpoints triggering de-escalation of therapy are resolution of vasospasm or a significant established infarction in the territory at risk. • The main therapeutic modalities are nimodipine, induced euvolemic hypertension, and endovascular therapy.
Heart Association and American Stroke Association (AHA/ASA) 4 divide management for patients following aneurysmal SAH into monitoring and treatment. Monitoring for DCI is clinical, radiographic, and physiological (Table 1) . Treatment and intervention usually depend on identifying triggers during monitoring and includes oral nimodipine, hemodynamic management, and endovascular intervention.
A. monItorIng
Serial neurological examinations, physiological monitoring, and radiological studies all have an essential role in identifying triggers for intervention ( Table 2) . Clinical examination mainly identifies new neurological deficits; it requires a skilled nursing staff and physicians to recognize subtle changes in the patient's neurological status which might be a sign of vasospasm and DCI. Neurological examination as a part of monitoring is essential despite its limitations in detecting subtle changes in poor grade patients.
Transcranial Doppler (TCD) is the most commonly used physiological modality to monitor for vasospasm. Transcranial Doppler is a noninvasive method for measuring cerebral vessels' diameter and blood flow velocity; a change in a vessel diameter will be inversely proportional to the blood flow velocity in the same vessel. 23 It is considered highly specific in detecting vasospasm in the MCA territory and a moderately sensitive diagnostic test when compared to conventional digital subtraction angiography (DSA) which is the gold standard for detection of cerebral arterial narrowing. 22 A systematic review of 26 reports which compared TCD to conventional angiography showed that TCD is unlikely to demonstrate middle cerebral artery (MCA) spasm if angiography fails to show it, i.e., a low false-positive rate. 24 Daily TCD is recommended and considered reasonable to monitor for vasospasm (Class IIa; Level of Evidence B). 4 The threshold is less than 120 cm/s for absence of vasospasm and more than 200 cm/s or a MCA mean cerebral blood flow velocity/extracranial internal carotid artery mean cerebral blood flow velocity more than 6 for the presence of vasospasm. 12 Other uncommon physiologic modalities for detecting DCI include brain tissue oxygen monitoring (PbtO 2 ), cerebral microdialysis (CMD), and electroencephalogram (EEG); 22 insufficient data are available at present regarding these modalities.
Radiographic monitoring includes conventional digital subtraction angiography (DSA) which is the gold standard diagnostic method, computed tomography scans which include CT angiography (CTA), and CT perfusion (CTP). Computed tomography angiography has been compared to DSA and has an 87% accuracy in detecting arterial vasospasm; using CTA as a diagnostic tool has a negative predictive value of 95% and helps avoid 83% of unnecessary DSA. 25 Another study showed a 95.2% agreement between CTA and DSA in the detection of vasospasm. 26 Computed tomography perfusion was found to be a superior diagnostic tool for DCI when compared to CTA; 27 the criteria for highest diagnostic accuracy with CTP are an increased mean transit time and decreased cerebral blood flow. 11, 27 Computed tomography angiography combined with CTP provides accurate screening to predict DCI. 28 Radiographic monitoring is considered a relatively accurate method of arterial vasospasm detection. However, it is not practical on a daily basis unlike TCD, since it carries risk of radiation exposure, and it is unreasonable to expose patients to daily intravenous contrast.
The severity of aneurysmal SAH is usually assessed by the Hunt and Hess scale which also predicts the survival and risks at the time of intervention. 29 The risk for vasospasm can be assessed by the Fisher 6 and the modified Fisher scales (Tables 3  and 4) . In low risk, good grade patients, it is practical to monitor them with neurological examinations and TCD; new deficits or increased velocities on TCD are an indication for further assessment using CTA, CTP, or DSA. 22 In high risk, good grade patients who previously underwent CTA, CTP, or DSA, changes in neurological status are an indication to start therapy with blood pressure elevation and endovascular intervention. Repeating CTA and CTP should be considered if there is any doubt about the cause of the new deficits or if therapeutic intervention is contraindicated or carries high risk. 22 In poor grade and sedated patients, clinical examination is very limited, and it is difficult to identify new neurological deficits. In these patients, a change in TCD velocities or the detection of vasospasm on routine CTA or DSA or perfusion deficits on CTP is an indication to initiate therapy for DCI, unless a significant infarction has developed. 
b. orAl nImodIpIne
Nimodipine is a calcium antagonist that is indicated in all patients with aneurysmal SAH starting from day 1 following aneurysmal rupture for 21 days, which is the time these patients are at risk for developing vasospasm. Nimodipine administration (Class I, Level of Evidence A) 4 is the only evidence-based pharmacologic therapy for improving outcomes following vasospasm. 30 It does not treat the vasospasm but improves the neurological outcomes by limiting DCI. Calcium antagonists decrease calcium influx to vascular smooth muscle by blocking calcium channels and thus decrease vasospasm. 31 Randomized trials showed the benefit of oral nimodipine in reducing poor outcomes and secondary ischemia; 30, 32 there is no proof that other routes like intravenous injection improve the outcomes. 31 The recommended dose of oral nimodipine is 60 mg every 4 hours given for the first 21 days after aneurysmal SAH.
c. mAgnesIum, stAtIns, And endotHelIn AntAgonIsts
Magnesium, which acts as a calcium channel blocker and NMDA-receptor antagonist, was hypothesized to decrease poor outcomes in patients with aneurysmal SAH. However, phase-III placebo control trials have failed to show that intravenous infusion of magnesium sulfate is superior to placebo. 33, 34 Statins have neuroprotective effects by antiinflammatory, antioxidant, and antithrombotic effects; 35 they reduce ischemic stroke risk. Considering these concepts, statins underwent randomized clinical trials aiming to improve outcomes in patients following aneurysmal SAH. As with magnesium, these drugs did not demonstrate any benefit either in short and long term outcomes or in reducing mortality. 36 Endothelin is a potent vasoconstrictor, and randomized control trials have been conducted to study the effect of endothelin receptor antagonists on the outcomes of SAH patients. The most recent metaanalysis of these trials concluded that there is no benefit in the outcomes. 
d. HemodynAmIc AugmentAtIon
The intention of hemodynamic augmentation is to improve cerebral blood flow (CBF) to optimize the cerebral perfusion pressure. Triple-H therapy (hypervolemia, hypertension, and hemodilution) was considered for many decades to increase cerebral blood flow in patients with aneurysmal SAH and to prevent and treat cerebral vasospasm. However, there is no strong evidence in the medical literature supporting this therapy since most of the studies were non-randomized. 22 At the current time, Triple-H therapy and its separate components have not been proven to increase CBF in SAH patients and there is no consensus that it should be used. 38 Hypervolemia has been compared to euvolemia in few prospective randomized studies. 39, 40 These studies failed to demonstrate any difference between hypervolemia and euvolemia to prevent or treat vasospasm. Hypervolemia might be associated with higher risk of complications, such as congestive heart failure and re-bleeding. 12, 39, 41 There are some physiological and observational human and animal data to suggest that hypervolemia does not increase cerebral perfusion pressure compared to euvolemia. Multiple modalities are used for volume status monitoring; these include clinical examination, fluid balance, daily weight, BUN: Cr ratio, central venous pressure, Swan-Ganz catheter, bedside critical care ultrasound, and non-invasive hemodynamic and cardiac monitoring (Table 5) .
Induced hypertension (Class I, Level of Evidence B) produces a modest increase in CBF and is recommended in patients with DCI, provided that the aneurysm has been secured. 4, 22, 38 The goal is to increase mean arterial pressure (MAP) by 20% or target a MAP at 100-110 mmHg. Some practitioners prefer to target the systolic blood pressure between 180-240 mmHg or MAP 110-140 mmHg. 42 Efforts to reach the target blood pressure in patients with congestive heart failure, myocardial ischemia, and other cardiac comorbidities may be limited to avoid other serious complications that might develop from cardiac decompensation. In patients with signs of vasospasm and an unsecured aneurysm, blood pressure elevation should be cautious. 22 The preferred vasopressors to induce hypertension are norepinephrine, phenylephrine, and possibly dopamine. 22 The results of the above recommendations and observations reflect a shift from Triple H therapy to euvolemic induced-hypertension for treatment of symptomatic cerebral vasospasm. As with all goal directed therapy in critical care, multiple modalities are often used, and care is individualized based on the patient's physiology at any given point in time.
e. HemodynAmIc AugmentAtIon
Intra-arterial infusion of vasodilators and balloon angioplasty are used independently or in combination for treatment of symptomatic vasospasm refractory to medical therapy to prevent worsening neurological deficits. Intra-arterial vasodilators for treatment of vasospasm include papaverine which is the most studied agent. However, with multiple reported side effects, it has been replaced with intra-arterial calcium channel blockers, including verapamil, nimodipine, and nicardipine. 43 Balloon angioplasty works by mechanical dilation of the intracranial vessels. It leads to durable results but is feasible only with the proximal cerebral vessels, the internal carotid artery, the middle cerebral artery M1 segment, the anterior cerebral artery A1 segment, the basilar artery, and the posterior cerebral artery P1 segment. Prophylactic transluminal balloon angioplasty prior to the onset of vasospasm within 96 hours after aneurysmal SAH in patients with Fisher grade III produced a significant decrease in the number of patients who needed therapeutic angioplasty, but it did not improve in clinical outcomes. Therefore, prophylactic angioplasty is not indicated in patients following aneurysmal SAH. 44 balloon angioplasty is reserved for patients with angiographic or clinical vasospasm. Endovascular treatment is repeated as needed, and there is no guideline about the appropriate time to discontinue endovascular management. This depends on the clinical judgement and expertise of the caring team, the response to treatment, the development of new neurological deficits, and the evolution of new infarcts on the follow up scans.
f. cessAtIon And de-escAlAtIng tHerApy
The main endpoint triggering de-escalation of therapy is resolution of vasospasm or established infarction in the territory at risk. In good grade patients, with improvement during clinical assessment, cautious de-escalation of therapy should be considered. This can be aided by physiological and TCD monitoring. In poor grade patients, confirmation with a serial TCD, CT perfusion, continuous EEG monitoring, PbtO 2 or • Non-invasive • Easy and quick tool for trained personnel
• Requires additional training of personnel
Non-invasive hemodynamic and cardiac output monitoring (Flow Trac® etc)
• Non-invasive • Continuous monitoring
• Impaired sensitivity and specificity in patients with cardiac arrhythmias microdialysis is required. If a significant infarction in the territory at risk is confirmed, therapy can be discontinued. 22 Nimodipine is discontinued after 21 days from the day of the hemorrhage.
conclusIons
Aneurysmal SAH is a serious neurological emergency associated with high morbidity and mortality that requires prompt intervention to secure the ruptured aneurysm. It should be managed in a high-volume center (centers managing >35 SAH/ year). Cerebral vasospasm is the most challenging complication that follows aneurysmal SAH. There is an evidence based consensus that all patients with aneurysmal SAH should be started with oral nimodipine for 21 days and close monitoring with frequent neurological checks and other diagnostic modalities like TCD, CTA, CTP and DSA. Depending on the triggers found during monitoring, patients might qualify for hemodynamic augmentation or endovascular treatment. Magnesium, statins, endothelin antagonists and hypervolemia therapy make no statistical differences in the neurological outcomes. Other monitoring modalities (like EEG, pbtO 2 , and micro dialysis) are still under investigation.
